Kaynaklar
- Fava GA, Ruini C, Belaise C. The concept of recovery in major depression. Psychol Med 2007; 37(3): 307–17.
- Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW. et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48(9): 851–5.
- Aydemir Ö, Ergün H, Soygür H, Kesebir S, Tulunay C. Major depresif bozuklukta yaşam kalitesi: kesitsel bir çalışma. Turk Psikiyatri Derg 2009; 20(3): 205–12.
- da Rocha NS, Power MJ, Bushnell DM, Fleck MP. Is there a measurement overlap between depressive symptoms and quality of life? Compr Psychiatry 2009; 50(6): 549–55.
- Moses T, Leuchter AF, Cook I, Abrams M. Does the clinical course of depression determine improvement in symptoms and quality of life? J Nerv Ment Dis 2006; 194(4): 241–8.
- Berlim MT, Pargendler J, Brenner J, Fleck MP. Significant improvement in the quality of life of Brazilian depressed outpatients 12 weeks following the start of antidepressants. Psychiatry Res 2007; 153(3): 253–9.
- Sobocki P, Ekman M, Agren H, Krakau I, Runeson B, Mårtensson B. et al. Health related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health 2007; 10(2): 153–60.
- Reed C, Monz BU, Perahia DG, Gandhi P, Bauer M, Dantchev N. et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord 2009; 113(3): 296–302.
- Trkulja V. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to- head randomized trials. Croat Med J 2010; 51(1): 61–73.
- Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009; 15;(2): CD006532.
- Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20(3): 131–7.
- Yevtushenko VY, Belous AI, Yevtushenko YG. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, doubleblind, active-controlled study in adult outpatients. Clin Ther 2007; 29(11): 2319–32.
- Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473–83.
- Koçyiğit H, Aydemir Ö, Ölmez N, Memiş A. Kısa Form-36 (KF-36)'nın Türkçe Versiyonunun Güvenilirliği ve Geçerliliği. İlaç ve Tedavi Dergisi 1999; 12(1): 102–6.
- Demiral Y, Ergör G, Ünal B, Semin S, Akvardar Y, Kıvırcık B. et. al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health 2006; 9: 247.
- EuroQoL Group. EuroQoL—a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3): 199–208.
- Eser E, Dinç G, Cambaz S, Özyurt B, Nesanır N, Şerifhan M, et al. EURO-QoL (EQ-5D) indeksinin toplum standartları ve psikometrik özellikleri: Manisa kent toplumu örneklemi. 2. Sağlıkta Yaşam Kalitesi Kongresi Bildiri Özetleri Kitabı Meta Basımevi, İzmir, 2007; p.78.
- Akdemir A, Örsel S, Dağ İ, Türkçapar H, İşcan N, Özbay H. Hamilton Depresyon Derecelendirme Ölçeği (HDDÖ)'nin geçerliği, güvenirliği ve klinikte kullanımı. Psikiyatri Psikoloji Psikofarmakoloji Dergisi 1996; 4(4): 251–9.
- Skevington SM, Wright A. Changes in the quality of life of patients receiving antidepressant medication in primary care: validation of the WHOQOL-100. Br J Psychiatry 2001; 178: 261–7.